English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.05 |
| Open | 1.05 |
| 1-Year Change | -35.98% |
| Day's Range | 1.01 - 1.05 |
Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.
BRIEF: For the nine months ended 30 September 2021, Unicycive Therapeutics Inc revenues was not reported. Net loss increased from $1.4M to $7.3M. Higher net loss reflects Research and development - Balancing v increase from $516K to $4.2M (expense), General and administrative - Balancing increase from $626K to $1.5M (expense), Interest expense increase from $81K to $628K (expense).
